DETOUR System
Endologix, LLC · Decision date Jan 22, 2026
What did the FDA approve?
FDA records P220021/S007 as a supplement to PMA P220021, with the supplement type “135 Review Track For 30-Day Notice”. The recorded decision is approval, dated Jan 22, 2026.
FDA approval order statement
changes to the stent graft lot release testing and criteria
- Regulatory pathway
- PMA supplement
- Supplement type
- 135 Review Track For 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 22, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P220021/S007
- Regulatory pathway
- PMA supplement
- Applicant
- Endologix, LLC
- Product code
- QWM
- Decision code
- APPR
- Decision date
- Jan 22, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Stent graft, bypass, superficial femoral artery.
- Applicant
- Endologix, LLC
- Product code
- QWM
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P220021. Subsequent supplements may change the device or its indications.
FDA decision timeline
P220021 · Original PMA
DETOUR System
P220021/S005 · Related supplement
DETOUR System
P220021/S007 received
Application receipt date recorded by FDA.
P220021/S006 · Related supplement
DETOUR System
P220021/S008 · Related supplement
DETOUR System
P220021/S007 · FDA decision
135 Review Track For 30-Day Notice
P220021/S009 · Related supplement
DETOUR System
Timeline entries are records held by MedtechLedger for P220021. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P220021
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
DETOUR SystemP220021 | Endologix, LLC | PMA approval | Jun 7, 2023 | FDA |
DETOUR SystemP220021/S005 | Endologix, LLC | PMA supplement | Sep 18, 2025 | FDA |
DETOUR SystemP220021/S006 | Endologix, LLC | PMA supplement | Oct 9, 2025 | FDA |
DETOUR SystemP220021/S008 | Endologix, LLC | PMA supplement | Dec 23, 2025 | FDA |
DETOUR SystemP220021/S009 | Endologix, LLC | PMA supplement | Oct 16, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Endologix, LLC
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 3910 Brickway Blvd., Santa Rosa, CA, 95403
Sources and methodology
- Original FDA record: P220021/S007
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



